

Human CDH17/Cadherin 17 Domain 5 Protein

Cat. No. CDH-HM35D

Description

Source	Recombinant Human CDH17/Cadherin 17 Domain 5 Protein is expressed from HEK293 with mFc (IgG2a) tag at the C-terminus. It contains Glu450-Phe566.
Accession	Q12864
Molecular Weight	The protein has a predicted MW of 39.06 kDa. Due to glycosylation, the protein migrates to 40-65 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1 EU per µg by the LAL method.
Purity	>95% as determined by Bis-Tris PAGE >95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22 µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

Liver-intestine cadherin (CDH17) has been known to function as a tumor stimulator and diagnostic marker for almost two decades. In vivo studies showed CDH17 knockout resulted in apoptotic PC tumor death through activating caspase-3 activity. Taken together, CDH17 functions as an oncogenic molecule critical to PC growth by regulating tumor apoptosis signaling pathways and CDH17 could be targeted to develop an anti-PC therapeutic approach.

Assay Data


Bis-Tris PAGE



Human CDH17 Domain 5 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data



The purity of Human CDH17 Domain 5 is greater than 95% as determined by SEC-HPLC.